Category Archives: Stem Cell Therapy

Breakthrough in delivery for cell and gene therapy products has led to a wave of M&A activity as big pharma aims not to miss out on the future of medicine

AIM healthcare index at the centre of innovation, has risen 6% YTD compared with the AIM all share, which has declined 7%

finnLife 50 index has also risen 6% in 2020 led by gains in Synairgen (+2,930%), Avacta (+654%), Omega Diagnostics (+322%) and Tiziana Life Sciences (+283%)

London 25 August 2020 Healthcare companies employing and developing cell and gene therapy (C>) are driving the next wave of innovation in the pharmaceutical industry, leading to increased M&A activity as big pharma aims not to miss out on the future of medicine. The AIM healthcare index has been at the centre of this innovation, rising 6% YTD compared with the AIM all share, which has declined 7%.

These are the findings of finnCaps new quarterly Life Sciences sector report, Rude Health.

Rather than just treating a disease and its symptoms, C> can target the underlying cause of a disease, with long-term benefits and curative potential. C> is now being realised on an applicable level, with many products already approved and the FDA expects to approve 10-20 products a year by 2025.

The financials of the sector are reflective of this rapid progress. In 2018, the market value of C> was $536 million - $1.07 billion; but by 2026 it is set to have a valuation of up to$35.4 billion. Given the high proportion of start-ups in the sector, M&A activity is on the rise, as evidenced by the $3 billion Astellas spent in January 2020 to acquire Audentes Therapeutics, specialists in genetics medicines.

In 2014/2015, M&A activity in the sector was $5 billion; by 2018/2019 it had surged 880% to $49 billion. Much of this is driven by big pharma firms not wanting to fall behind their smaller, more versatile competition, as they did with monoclonal antibody technology. Consequently, they have engaged with M&A to speed up and enhance their own R&D efforts.

The report notes that innovators in C> will be well placed to take part in the land grab that will follow as a result of continued advancements in the sector, and highlights now as a good time for investors and pharmaceutical companies to become involved as the sector is rapidly maturing past its high potential research and development stage with an established pipeline of therapies already being developed.

Some of the key reasons why the report considers the C> sector to be an attractive one for investment are:

Pharmas next wave of innovation. C>s can be potentially curative treatment options as they usually target the underlying cause of disease. In the long term, these therapies could become the backbone of treatment regimens, and solutions to various unmet needs.

Deals. Big Pharma had to play catch-up with monoclonal antibody technology and seems determined not to make the same mistake with C>, as reflected in the high deal activity and high deal values seen within this space.

Sector maturation. Advances in the sector mean that the C> sector is beginning to mature beyond the R&D stage and into commercialisation, with some products already approved, and with a very large future pipeline of therapies.

Revenue.Therapies in this space can command high prices, allowing for high revenue generation, even from rare diseases and limited patient populations.

Despite its vital role in the future of medicine, C> also comes with challenges. The report highlights that the manufacture of C>s is difficult given they are, by definition, personalised for the patient. This means they cannot be batch produced for distribution to multiple patients as more traditional medicines can. For example, Zolgensma, which treats those with motor neurone disease, is priced at $2.1 (1.6) million per therapy, making it the most expensive drug treatment ever.

The report also notes how the payment process for C> requires a reworking of reimbursement systems not used to outlaying so much money up front for a treatment with long-term benefits/curative potential versus continuous, and lower payments for ongoing medicine treatment.

The technologies the report shines a spotlight include CAR-T therapy, stem cell therapy, CRISPR, RNA therapies, among various others.

Arshad Ahad, Research Analyst, Life Sciences, at finnCap, commented:Few technologies in the life sciences sector hold as much promise as Cell and Gene Therapy, with its ability to provide long-term benefits and curative potential. These technologies have been seen as the future of medicine for many years, and now we are closer than ever to that future becoming a reality. If Cell and Gene therapy does become the backbone of treatment regimes in the future, similar to the rise of monoclonal antibodies, then the companies involved are developing expertise in a critical part of the life sciences industry, which should confer a significant competitive advantage as the sector matures further. Now is therefore a good time to invest in the future.

Original post:
FINNCAP'S LIFE SCIENCES REPORT INDICATES CELL AND GENE THERAPY SECTOR IS DRIVING THE NEXT WAVE OF INNOVATION IN PHARMA - PharmiWeb.com

NEW YORK, Aug. 26, 2020 (GLOBE NEWSWIRE) --Mesoblast Limited(Nasdaq: MESO; ASX: MSB) today reported operational highlights and financial results for the fourth quarter and full-year ended June 30, 2020 (FY2020).

Mesoblast Chief Executive Dr Silviu Itescu stated: We are very pleased to report the significant corporate progress made by the Company over the last financial year. The most notable achievement was the successful FDA Advisory Committee meeting held this month which resulted in an overwhelmingly positive vote in favor of the efficacy of our lead product candidate remestemcel-L (RYONCIL) for children with steroid-refractory acute graft versus host disease (aGVHD). We are working closely with the FDA ahead of next months approval action date and are well prepared for a potential US launch during Q4 2020, with inventory build and a commercial organization in place.

In parallel, based on its anti-inflammatory effects in aGVHD, we have positioned remestemcel-L to address the most significant inflammatory complications in children and adults infected with COVID-19.Our randomized controlled Phase 3 trial continues to enroll adults in the US with acute respiratory distress syndrome, aiming to reduce the primary cause of mortality due to COVID-19 infection. We have also made remestemcel-L available to physicians for treatment ofCOVID-19 infected children with multisystem inflammatory syndrome (MIS-C) involving the heart under our Expanded Access Program.

We look forward to the upcoming results of our COVID-19 studies and the Phase 3 trials for chronic advanced heart failure and discogenic low back pain.

Financial Highlights

US Market Opportunity for RYONCIL

Operational Highlights for Phase 3 Product Candidates

Mesoblast is developing culture expanded allogeneic cellular medicines based on its proprietary remestemcel-L and rexlemestrocel mesenchymal lineage cell technology platforms. The product candidates derived from these cell platforms share mechanisms of action that counteract the cytokine storms implicated in various inflammatory conditions by reducing pro-inflammatory cytokines, increasing anti-inflammatory cytokines, and recruiting anti-inflammatory cells to involved tissues.

Remestemcel-L (RYONCIL) for Pediatric SR-aGVHD

On August 13, 2020, the Oncologic Drugs Advisory Committee (ODAC) of the United States Food and Drug Administration (FDA) voted 9-18 in favor that the available data support the efficacy of remestemcel-L (RYONCIL) in pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD), a life-threatening complication of a bone marrow transplant. The ODAC is an independent panel of experts that evaluates efficacy and safety of data and makes appropriate recommendations to the FDA.Although the FDA will consider the recommendation of the panel, the final decision regarding the approval of the product is made by the FDA solely, and the recommendations by the panel are non-binding.

The Biologics License Application (BLA) for RYONCIL is under Priority Review by the FDA with an action date of September 30, 2020, under the Prescription Drug User Fee Act (PDUFA). If approved by the PDUFA date, Mesoblast plans to launch RYONCIL in the US in Q4 CY2020 in children and adolescents up to 18 years old.There are currently no FDA-approved treatments in the US for children under 12 with SR-aGVHD.

Remestemcel-L for Adults With SR-aGVHD

Beyond pediatric SR-aGVHD, Mesoblast will seek to obtain approval for RYONCIL in adults with the most severe forms of SR-aGVHD. In an earlier randomized placebo-controlled Phase 3 trial, a post-hoc analysis showed that remestemcel-L was associated with an increased Day 28 overall response in steroid-refractory patients with Grade C/D disease.This patient population continues to represent a high-risk population with poor overall survival, and in August 2020 Mesoblast convened an advisory meeting with key opinion leaders to develop a clinical trial design for a post-market study evaluating remestemcel-L in this patient population.

Remestemcel-L for Adults with COVID-19 Acute Respiratory Distress Syndrome (ARDS)

Despite improvements in the treatment of COVID-19, mortality remains high, particularly in patients with cytokine storm and ARDS who require mechanical ventilation.A pilot study in 12 COVID-19 patients with moderate to severe ARDS treated with remestemcel-L under emergency compassionate use at Mt Sinai Hospital in New York demonstrated promising results, with 75% of patients successfully taken off a ventilator and discharged from hospital within a median of 10 days.In order to definitively determine the safety and efficacy of these data, a Phase 3 randomized controlled trial is being conducted in 300 ventilator-dependent patients with moderate to severe COVID-19 ARDS.9 Up to 30 leading medical centers across the US are taking part in the trial, which is expected to complete recruitment during Q4 CY2020.

Patients in the Phase 3 trial are randomized 1:1 to receive either two intravenous infusions of remestemcel-L within five days or placebo on top of maximal care. The primary endpoint is all-cause mortality within 30 days of randomization, with the key secondary endpoint being the number of days off mechanical ventilator support.

Anindependent Data Safety Monitoring Board (DSMB)has set a review date of early September for its first interim analysis of thePhase 3 trialofremestemcel-L in ventilator-dependentCOVID-19patients with moderate to severe ARDS.The DSMB will review safety and efficacy data from the first 90 patients after they have all completed 30 days of follow up and will inform Mesoblast on whether to proceed as planned to full enrollment of 300 patients or to stop the trial early.

Remestemcel-L Expanded Access Program (EAP)forChildren With COVID-19 Multisystem Inflammatory Syndrome (MIS-C)

Children hospitalized with COVID-19 infection are at risk of both ARDS, seen in 22% of children,10 and a life-threatening inflammation called MIS-C which in approximately 50% of cases is associated with significant cardiovascular complications resulting in decreased heart function and dilation of coronary arteries.11-13.

Mesoblast has established an EAP which provides physicians with access to use remestemcel-L in COVID-19 infected children aged between two months and 17 years with cardiovascular and other complications of MIS-C under the Companys existing Investigational New Drug (IND) application with the FDA. 14 The first patient has received treatment under the EAP and has been discharged from the hospital. Mesoblast will continue to monitor the outcome in all MIS-C patients treated under the EAP to establish the safety and effectiveness of the protocol in children with this potentially life-threatening complication of COVID-19.

Rexlemestrocel (REVASCOR) for Advanced Chronic Heart Failure

In the United States alone, of more than 6.5 million patients with chronic heart failure, there are more than 1.3 million patients with advanced stage of the disease who have high rates of morbidity and mortality despite maximal existing therapies.15The objective of treatment with Mesoblasts allogeneic cell therapy REVASCOR is to reduce or reverse the severe inflammatory process in the damaged heart of these patients, and thereby prevent or delay further progression of heart failure or death.

Mesoblasts 566-patient Phase 3 randomized controlled trial of REVASCOR for advanced heart failure has completed patient follow-up and all events have been independently adjudicated.While the COVID-19 pandemic has delayed completion of data quality review at the study sites, the Phase 3 trial data readout is expected during Q4 CY2020.

In parallel, Mesoblasts partner in China, Tasly Pharmaceuticals, is leveraging the results of this trial in its discussions with the Chinese regulatory authority.

In an earlier randomized placebo-controlled 60-patient Phase 2 trial, a single intra-myocardial injection of REVASCOR at the dose administered in the subsequent Phase 3 trial prevented any hospitalizations or deaths over three years of follow-up in patients with advanced chronic heart failure.

Additionally, in results presented at the 2020 American College of Cardiology Virtual Scientific Sessions from 70 patients with end-stage ischemic heart failure and a Left Ventricular Assist Device (LVAD), a sub-study of 159 patients randomized to either REVASCOR or saline, a single intra-myocardial injection of REVASCOR at the dose administered in the Phase 3 trial resulted in a beneficial effect on LVAD weaning, hospital readmissions for heart failure, and major mucosal bleeding events. These end-stage ischemic heart failure patients closely resemble the majority of patients enrolled in the Phase 3 randomized controlled trial of REVASCOR for advanced chronic heart failure.

Rexlemestrocel (MPC-06-ID) for Chronic Low Back Pain

Mesoblasts MPC-06-ID development program targets over 3.2 million patients in the United States and 4 million in the E.U.5 with chronic low back pain due to moderate to severe inflammatory disc degeneration.16 Back pain causes more disability than any other condition and inflicts substantial direct and indirect costs on the healthcare system, including excessive use of opioids in this patient population.There is a significant need for a safe, efficacious and durable treatment in patients with chronic low back pain due to severely inflamed degenerative disc disease.

While the COVID-19 pandemic has delayed completion of data quality review at the study sites, data readout for the 2:1 randomized placebo-controlled US Phase 3 trial in 404 patients is expected during Q4 CY2020. Mesoblast continues to collaborate closely with Grnenthal on the clinical protocol for a confirmatory Phase 3 trial in Europe for MPC-06-ID in chronic low back pain due to degenerative disc disease, with the results of this and the US Phase 3 trial expected to support both FDA and European Medicines Agency regulatory approvals.

Manufacturing

During fiscal 2020, Mesoblast established a commercial supply agreement with Lonza ahead of the potential FDA approval and commercial launch of RYONCIL.This agreement has facilitated inventory build in preparation for the potential product launch. Manufacturing is also being scaled-up to meet projected increase in capacity requirements for potential label extensions of RYONCIL such as COVID-19 ARDS.

Mesoblast has proprietary technology that facilitates the increase in yields necessary for the long-term commercial supply of its product candidates, and next generation manufacturing processes using xeno-free technologies and three-dimensional bioreactors to reduce labor, drive down cost of goodsand improve manufacturing efficiencies.

Intellectual Property

Mesoblast has an extensive patent portfolio with over 1,100 patents and patent applications across 82 patent families, and patent terms extending through 2040. These patents cover composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells, and provide strong commercial protection for our products in all major markets, including the United States, Europe, Japan and China.

Licensing agreements with JCR, Grnenthal, Tasly and Takeda highlight the strength of Mesoblast's extensive intellectual property portfolio covering mesenchymal lineage cells. Mesoblast will continue to use its patents to prosecute its commercial rights as they relate to its core strategic product portfolio. When consistent with the Companys strategic objectives, it may consider providing third parties with commercial access to its patent portfolio.

Financial Results for the Year Ended June 30, 2020 (FY2020):

Loss after taxreduced by US$11.9 million to US$77.9 million for FY2020 compared to US$89.8 million for FY2019 as detailed below:Revenuesincreased US$15.4 million to US$32.2 million for FY2020, compared to US$16.7 million for FY2019.

Research and Developmentexpenses decreased by US$3.6 million to US$56.2 million for FY2020, compared to US$59.8 million for FY2019. The total reduction in overall R & D costs due to savings on Phase 3 clinical trials was US$8.6 million, offset by our investment in pre-commercial activities as we prepare for the potential launch of RYONCIL in the United States.Manufacturingexpenses increased by US$9.9 million to US$25.3 million for FY2020, compared to US$15.4 million for FY2019 due to increased expenditure on pre-launch inventory for the potential launch of RYONCIL and clinical supply for the COVID-19 ARDS phase 3 trial offset by a reduction in manufacturing activities related to filing the Biologics License Application (BLA) for this product.

Management and Administrationexpenses increased US$4.0 million to US$25.6 million for FY2020, compared with US$21.6 million for FY2019, primarily due to non-cash share-based payments to employees and consultants.

Finance Costsfor borrowing arrangements with Hercules and NovaQuest were US$13.3 million for FY2020, compared to US$11.3 million for FY2019, an increase of US$2.0 million.Income taxbenefitincreased by US$0.5 million to US$9.4 million for FY2020, compared with US$8.9 million for FY2019 in relation to deferred tax liabilities recognized on the balance sheet during the period.

The net loss attributable to ordinary shareholders was 14.74 US cents per share for FY2020, compared with 18.16 US cents per share for FY2019.

Conference Call DetailsThere will be a webcast today on the financial results beginning at 8am AEST (Thursday, August 27, 2020); 6pm EDT (Wednesday, August 26, 2020). It can be accessed viahttps://webcast.boardroom.media/mesoblast-limited/20200826/NaN5f2ba898ed347b00198de987

The archived webcast will be available on the Investor page of the Companys website: http://www.mesoblast.com

References1.TEMCELL HS. Inj.is a registered trademark of JCR Pharmaceuticals Co. Ltd.2.Cash on hand at June 30, 2020 has been translated from US$ to A$ at a spot rate of 1.457.3.Proceeds from the May 13, 2020 placement have been translated from A$ to US$ at a spot rate of 0.651.4.Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT) - Activities and Outcomes of Hematopoietic Cell Transplantation in Japan 2018.5.Westin, J., Saliba, RM., Lima, M. (2011) Steroid-refractory acute GVHD: predictors and outcomes. Advances in Hematology.6.CIBMTR Current Uses and Outcomes of Hematopoietic Cell Transplantation 2017 Summary. Passweg JR, Baldomero, H (2016) Hematopoietic stem cell transplantation in Europe 2014: more than 40,000 transplants annually.7.Risk factors for acute GVHD and survival after hematopoietic cell transplantation - Blood 2012 119:296-307; Madan Jagasia et al.8.This vote includes a change to the original vote by one of the ODAC panel members after electronic voting closed.9. https://clinicaltrials.gov/ct2/show/NCT0437139310.Chao JY et al. J Pediatr 2020;223:14-911.Lancet2020; May 7. DOI: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31094-112.Lancet2020; May 13 DOI:https://doi.org/10.1016/S0140-6736(20)31103-X13.https://www.nejm.org/doi/full/10.1056/NEJMoa202175614.https://clinicaltrials.gov/ct2/show/NCT0445643915.AHAs 2017 Heart Disease and Stroke Statistics16.Decision Resources: Chronic Pain December 2015.

About MesoblastMesoblast Limited (Nasdaq: MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. The Companys proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblasts Biologics License Application to seek approval of its product candidate RYONCIL (remestemcel-L) for pediatric steroid-refractory acute graft versus host disease has been accepted for priority review by the United States Food and Drug Administration (FDA), and if approved, product launch in the United States is expected in 2020. Remestemcel-L is also being developed for other inflammatory diseases in children and adults including moderate to severe acute respiratory distress syndrome (ARDS). Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblasts licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see http://www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking StatementsThis announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward- looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblasts preclinical and clinical studies, and Mesoblasts research and development programs; Mesoblasts ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblasts ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblasts product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblasts product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblasts ability to enter into and maintain established strategic collaborations; Mesoblasts ability to establish and maintain intellectual property on its product candidates and Mesoblasts ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblasts expenses, future revenues, capital requirements and its needs for additional financing; Mesoblasts financial performance; developments relating to Mesoblasts competitors and industry; and the pricing and reimbursement of Mesoblasts product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblasts actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive, as approved by the Board of Directors.

For further information, please contact:

Consolidated Income Statement

Consolidated Statement of Comprehensive Income

Consolidated Balance Sheet

Consolidated Statement of Cash Flows

Original post:
Mesoblast Reports Substantial Operational Progress and Financial Results for the Year Ended June 30, 2020Mesoblast Well Prepared Ahead of First...

Allogeneic Stem Cell Therapy Market Los Angeles, United State- The global Allogeneic Stem Cell Therapy market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Allogeneic Stem Cell Therapy market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Allogeneic Stem Cell Therapy Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Allogeneic Stem Cell Therapy market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Allogeneic Stem Cell Therapy market.

Leading players of the global Allogeneic Stem Cell Therapy market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Allogeneic Stem Cell Therapy market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Allogeneic Stem Cell Therapy market. It also provides useful recommendations for new as well as established players of the global Allogeneic Stem Cell Therapy market.

Get PDF template of this report: https://www.qyresearch.com/sample-form/form/2043756/global-and-china-allogeneic-stem-cell-therapy-market

Allogeneic Stem Cell Therapy Market Leading Players

, Escape Therapeutics, Inc., Lonza Group Ltd., Osiris Therapeutics (Smith & Nephew), NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Anterogen, MolMed S.p.A., Takeda (TiGenix)

Allogeneic Stem Cell Therapy Segmentation by Product

, Adult Stem Cell Therapy, Human Embryonic Stem Cell Therapy, Induced Pluripotent Stem Cell Therapy, Others Allogeneic Stem Cell Therapy

Allogeneic Stem Cell Therapy Segmentation by Application

Musculoskeletal Disorder, Wounds & Injuries, Cardiovascular Diseases, Others

Report Objectives

Analyzing the size of the global Allogeneic Stem Cell Therapy market on the basis of value and volume.

Accurately calculating the market shares, consumption, and other vital factors of different segments of the global Allogeneic Stem Cell Therapy market.

Exploring the key dynamics of the global Allogeneic Stem Cell Therapy market.

Highlighting important trends of the global Allogeneic Stem Cell Therapy market in terms of production, revenue, and sales.

Deeply profiling top players of the global Allogeneic Stem Cell Therapy market and showing how they compete in the industry.

Studying manufacturing processes and costs, product pricing, and various trends related to them.

Showing the performance of different regions and countries in the global Allogeneic Stem Cell Therapy market.

Forecasting the market size and share of all segments, regions, and the global market.

Enquire for customization in Report @https://www.qyresearch.com/customize-request/form/2043756/global-and-china-allogeneic-stem-cell-therapy-market

Table of Contents.

1 Report Overview1.1 Study Scope1.2 Market Analysis by Type1.2.1 Global Allogeneic Stem Cell Therapy Market Size Growth Rate by Type: 2020 VS 20261.2.2 Adult Stem Cell Therapy1.2.3 Human Embryonic Stem Cell Therapy1.2.4 Induced Pluripotent Stem Cell Therapy1.2.5 Others1.3 Market by Application1.3.1 Global Allogeneic Stem Cell Therapy Market Share by Application: 2020 VS 20261.3.2 Musculoskeletal Disorder1.3.3 Wounds & Injuries1.3.4 Cardiovascular Diseases1.3.5 Others1.4 Study Objectives1.5 Years Considered 2 Global Growth Trends2.1 Global Allogeneic Stem Cell Therapy Market Perspective (2015-2026)2.2 Global Allogeneic Stem Cell Therapy Growth Trends by Regions2.2.1 Allogeneic Stem Cell Therapy Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Allogeneic Stem Cell Therapy Historic Market Share by Regions (2015-2020)2.2.3 Allogeneic Stem Cell Therapy Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Market Restraints 3 Competition Landscape by Key Players3.1 Global Top Allogeneic Stem Cell Therapy Players by Market Size3.1.1 Global Top Allogeneic Stem Cell Therapy Players by Revenue (2015-2020)3.1.2 Global Allogeneic Stem Cell Therapy Revenue Market Share by Players (2015-2020)3.2 Global Allogeneic Stem Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Players Covered: Ranking by Allogeneic Stem Cell Therapy Revenue3.4 Global Allogeneic Stem Cell Therapy Market Concentration Ratio3.4.1 Global Allogeneic Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)3.4.2 Global Top 10 and Top 5 Companies by Allogeneic Stem Cell Therapy Revenue in 20193.5 Key Players Allogeneic Stem Cell Therapy Area Served3.6 Key Players Allogeneic Stem Cell Therapy Product Solution and Service3.7 Date of Enter into Allogeneic Stem Cell Therapy Market3.8 Mergers & Acquisitions, Expansion Plans 4 Allogeneic Stem Cell Therapy Breakdown Data by Type (2015-2026)4.1 Global Allogeneic Stem Cell Therapy Historic Market Size by Type (2015-2020)4.2 Global Allogeneic Stem Cell Therapy Forecasted Market Size by Type (2021-2026) 5 Allogeneic Stem Cell Therapy Breakdown Data by Application (2015-2026)5.1 Global Allogeneic Stem Cell Therapy Historic Market Size by Application (2015-2020)5.2 Global Allogeneic Stem Cell Therapy Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Allogeneic Stem Cell Therapy Market Size (2015-2026)6.2 North America Allogeneic Stem Cell Therapy Market Size by Type (2015-2020)6.3 North America Allogeneic Stem Cell Therapy Market Size by Application (2015-2020)6.4 North America Allogeneic Stem Cell Therapy Market Size by Country (2015-2020)6.4.1 United States6.4.2 Canada 7 Europe7.1 Europe Allogeneic Stem Cell Therapy Market Size (2015-2026)7.2 Europe Allogeneic Stem Cell Therapy Market Size by Type (2015-2020)7.3 Europe Allogeneic Stem Cell Therapy Market Size by Application (2015-2020)7.4 Europe Allogeneic Stem Cell Therapy Market Size by Country (2015-2020)7.4.1 Germany7.4.2 France7.4.3 U.K.7.4.4 Italy7.4.5 Russia7.4.6 Nordic7.4.7 Rest of Europe 8 China8.1 China Allogeneic Stem Cell Therapy Market Size (2015-2026)8.2 China Allogeneic Stem Cell Therapy Market Size by Type (2015-2020)8.3 China Allogeneic Stem Cell Therapy Market Size by Application (2015-2020)8.4 China Allogeneic Stem Cell Therapy Market Size by Region (2015-2020)8.4.1 China8.4.2 Japan8.4.3 South Korea8.4.4 Southeast Asia8.4.5 India8.4.6 Australia8.4.7 Rest of Asia-Pacific 9 Japan9.1 Japan Allogeneic Stem Cell Therapy Market Size (2015-2026)9.2 Japan Allogeneic Stem Cell Therapy Market Size by Type (2015-2020)9.3 Japan Allogeneic Stem Cell Therapy Market Size by Application (2015-2020)9.4 Japan Allogeneic Stem Cell Therapy Market Size by Country (2015-2020)9.4.1 Mexico9.4.2 Brazil 10 South Korea10.1 South Korea Allogeneic Stem Cell Therapy Market Size (2015-2026)10.2 South Korea Allogeneic Stem Cell Therapy Market Size by Type (2015-2020)10.3 South Korea Allogeneic Stem Cell Therapy Market Size by Application (2015-2020)10.4 South Korea Allogeneic Stem Cell Therapy Market Size by Country (2015-2020)10.4.1 Turkey10.4.2 Saudi Arabia10.4.3 UAE10.4.4 Rest of Middle East & Africa 11 Key Players Profiles11.1 Escape Therapeutics, Inc.11.1.1 Escape Therapeutics, Inc. Company Details11.1.2 Escape Therapeutics, Inc. Business Overview11.1.3 Escape Therapeutics, Inc. Allogeneic Stem Cell Therapy Introduction11.1.4 Escape Therapeutics, Inc. Revenue in Allogeneic Stem Cell Therapy Business (2015-2020))11.1.5 Escape Therapeutics, Inc. Recent Development11.2 Lonza Group Ltd.11.2.1 Lonza Group Ltd. Company Details11.2.2 Lonza Group Ltd. Business Overview11.2.3 Lonza Group Ltd. Allogeneic Stem Cell Therapy Introduction11.2.4 Lonza Group Ltd. Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.2.5 Lonza Group Ltd. Recent Development11.3 Osiris Therapeutics (Smith & Nephew)11.3.1 Osiris Therapeutics (Smith & Nephew) Company Details11.3.2 Osiris Therapeutics (Smith & Nephew) Business Overview11.3.3 Osiris Therapeutics (Smith & Nephew) Allogeneic Stem Cell Therapy Introduction11.3.4 Osiris Therapeutics (Smith & Nephew) Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.3.5 Osiris Therapeutics (Smith & Nephew) Recent Development11.4 NuVasive11.4.1 NuVasive Company Details11.4.2 NuVasive Business Overview11.4.3 NuVasive Allogeneic Stem Cell Therapy Introduction11.4.4 NuVasive Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.4.5 NuVasive Recent Development11.5 Chiesi Pharmaceuticals11.5.1 Chiesi Pharmaceuticals Company Details11.5.2 Chiesi Pharmaceuticals Business Overview11.5.3 Chiesi Pharmaceuticals Allogeneic Stem Cell Therapy Introduction11.5.4 Chiesi Pharmaceuticals Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.5.5 Chiesi Pharmaceuticals Recent Development11.6 JCR Pharmaceutical11.6.1 JCR Pharmaceutical Company Details11.6.2 JCR Pharmaceutical Business Overview11.6.3 JCR Pharmaceutical Allogeneic Stem Cell Therapy Introduction11.6.4 JCR Pharmaceutical Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.6.5 JCR Pharmaceutical Recent Development11.7 Pharmicell11.7.1 Pharmicell Company Details11.7.2 Pharmicell Business Overview11.7.3 Pharmicell Allogeneic Stem Cell Therapy Introduction11.7.4 Pharmicell Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.7.5 Pharmicell Recent Development11.8 Anterogen11.8.1 Anterogen Company Details11.8.2 Anterogen Business Overview11.8.3 Anterogen Allogeneic Stem Cell Therapy Introduction11.8.4 Anterogen Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.8.5 Anterogen Recent Development11.9 MolMed S.p.A.11.9.1 MolMed S.p.A. Company Details11.9.2 MolMed S.p.A. Business Overview11.9.3 MolMed S.p.A. Allogeneic Stem Cell Therapy Introduction11.9.4 MolMed S.p.A. Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.9.5 MolMed S.p.A. Recent Development11.10 Takeda (TiGenix)11.10.1 Takeda (TiGenix) Company Details11.10.2 Takeda (TiGenix) Business Overview11.10.3 Takeda (TiGenix) Allogeneic Stem Cell Therapy Introduction11.10.4 Takeda (TiGenix) Revenue in Allogeneic Stem Cell Therapy Business (2015-2020)11.10.5 Takeda (TiGenix) Recent Development 12 Analysts Viewpoints/Conclusions 13 Appendix13.1 Research Methodology13.1.1 Methodology/Research Approach13.1.2 Data Source13.2 Disclaimer13.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

Continue reading here:
Allogeneic Stem Cell Therapy Market Study for 2020 to 2026 Providing Information on Key Players, Growth Drivers and Industry Challenges|Escape...

New Study on the Global Animal Stem Cell Therapy Market by PMR

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Animal Stem Cell Therapy market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Animal Stem Cell Therapy market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Animal Stem Cell Therapy market to assist our clients arrive at beneficial business decisions.

As per the report, the global Animal Stem Cell Therapy market is expected to grow at a CAGR of ~XX% during the stipulated timeframe owing to a range of factors including, favorable government policies, and growing awareness related to the Animal Stem Cell Therapy , surge in research and development and more.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14941

Resourceful insights enclosed in the report:

Competitive Outlook

The competitive outlook section provides valuable information related to the different companies operating in the current Animal Stem Cell Therapy market landscape. The market share, product portfolio, pricing strategy, sales and distribution channels of each company is discussed in the report.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14941

Prominent players covered in the report are:

Regional Assessment

The presented market study touches upon the market scenario in different regions and provides a deep understanding of the influence of micro and macro-economic factors on the prospects of the market in each region.

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14941

The market report addresses the following queries related to the Animal Stem Cell Therapy market:

Go here to read the rest:
Animal Stem Cell Therapy to Hit a Market Value of US$ by 2017 2025 - StartupNG

NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company and the New York Stem Cell Foundation (NYSCF) Research institute today announced the filing of a provisional patent application with the U.S. Patent & Trademark Office (USPTO) for the differentiation of Natural Killer (NK) cells from induced pluripotent stem cells (iPSCs). The NYSCF Research Institute is a pioneer and acknowledged leader in stem cell technology, having developed the NYSCF Global Stem Cell Array®, the premier automated robotic platform for reprogramming skin or blood into induced pluripotent stem cells (iPSCs) and differentiating them into disease-relevant cell types.

Cytovia and NYSCF are also collaborating on the process development of Good Manufacturing Practices (GMP) of iPSC NK and CAR-NK cells with the potential to file additional patents on the engineering, expansion and GMP manufacturing processes of iPSC NK cells to treat cancer.

Dr. Daniel Teper, CEO of Cytovia commented, This first patent application filing on iPSC-NK cells is an important milestone for Cytovia, positioning us as a pioneer in this emerging field. The use of iPSC-NK cells constitutes a transformational approach to cancer treatment, enabling the use of precision cell therapy for many patients. Cytovia plans to initiate first clinical trials with iPSC NK-cells in 2021.

Susan L Solomon, Chief Executive Officer of NYSCF added, We are delighted by the progress made by the NYSCF and Cytovia team in the differentiation and expansion of NK cells from an iPSC source. These iPSC-NK cells can be genetically modified to create iPSC-CAR-NK cells. In the coming months, the collaboration will focus on developing a standardized GMP process to support Cytovia’s iPSC-NK and iPSC-CAR NK therapeutic candidates for cancer.”

ABOUT CAR NK CELL THERAPY Chimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR-NK cell therapy has demonstrated initial clinical relevance without the limitations of CAR-T, such as Cytokine Release Syndrome, neurotoxicity or Graft vs Host Disease (GVHD). Induced Pluripotent Stem Cells (iPSC) - derived CAR-NKs are naturally allogeneic, available off-the-shelf and may be able to be administered on an outpatient basis. Recent innovative developments with the iPSC, an innovative technology, allow large quantities of homogeneous genetically modified CAR NK cells to be produced from a master cell bank, and thus hold promise to expand access of cell therapy for many patients.

ABOUT THE NEW YORK STEM CELL FOUNDATION RESEARCH INSTITUTE The New York Stem Cell Foundation (NYSCF) Research Institute is an independent non-profit organization accelerating cures and better treatments for patients through stem cell research. The NYSCF global community includes over 190 researchers at leading institutions worldwide, including the NYSCF Druckenmiller Fellows, the NYSCF Robertson Investigators, the NYSCF Robertson Stem Cell Prize Recipients, and NYSCF Research Institute scientists and engineers. The NYSCF Research Institute is an acknowledged world leader in stem cell research and in the development of pioneering stem cell technologies, including the NYSCF Global Stem Cell Array®, which is used to create cell lines for laboratories around the globe. In 2019, NYSCF launched the Women’s Reproductive Cancers Initiative, which aims to shift paradigms in the way these cancers are studied and treated, in collaboration with leading cancer experts across the globe. NYSCF focuses on translational research in an accelerator model designed to overcome barriers that slow discovery and replace silos with collaboration. For more information, visit http://www.nyscf.org

ABOUT CYTOVIA THERAPEUTICS, INC Cytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem, and CytoImmune Therapeutics. Learn more at http://www.cytoviatx.com

For more information please contact:

Read more:
Cytovia Therapeutics and NYSCF Announce Filing of Provisional Patent for iPSC-Derived NK Cells to Produce Unlimited On-Demand NK and CAR-NK Cells for...

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Regenerative Medicine market.

Trusted Business Insights presents an updated and Latest Study on Regenerative Medicine Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Regenerative Medicine market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2020 2029 (Includes COVID-19 Business Impact)

The global regenerative medicine market size was USD 23,841.5 Million in 2018 and is Projected to Reach USD 151,949.5 Million by 2026, Exhibiting a CAGR of 26.1% between 2019 and 2026.

We have updated Regenerative Medicine Market with respect to COVID-19 Impact.Inquire before buying

Regenerative medicine (RM) involves using cells, tissues, or genetic material to treat and manage diseases. Regenerative medicine is an emerging field that aims to repair, replace or regenerate damaged tissue or organ. The U.S. National Institutes of Health includes cell therapy, gene therapy, biomaterials and tissue engineering into regenerative medicine. Regenerative medicine holds potential to treat incurable chronic diseases and conditions such as Alzheimer disease, Parkinsons disease, diabetes and others. According to the Alliance for Regenerative Medicine, approximately around 1,028 clinical trials are ongoing on regenerative medicine worldwide. Around USD 13.3 Bn global financing were raised in 2018 by investment into regenerative medicine. The increased investment by key market players in the research and development of the regenerative medicine is one of the major factor anticipated to drive the regenerative medicine market growth during the forecast period.

Market Segmentation

Increased investment in the research and development of regenerative by the key market players is one of the major factor driving the global market

Increasing investment by private and government organization in the development of the regenerative medicine is one of the factors expected to propel regenerative medicine industry dynamics. For instance, in March 2018, SanBio Group signed an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LLC for the development and contract manufacturing of regenerative medicines. Rising prevalence of chronic and genetic disorders and increased healthcare expenditure by developed and developing countries are some of the key factors impelling the regenerative medicine market growth.

Additionally, presence of the strong product pipeline in stem cell and gene therapy by various research institutes and key market players is one if the major factor anticipated to boost the growth of the market during the forecast period of 2018-2026. However, the growing demand for organ transplantation in developed and developing countries and the commercialization of regenerative medicine are some of the key elements anticipated to supplement the growth of the regenerative medicine market trends throughout the forecast period. Increased use of skin substitutes, grafts, bone matrix and other tissue engineered regenerative medicine is one of the prominent factor for the growth of the market.

Based on the type, the regenerative medicine industry segments includes cell therapy, gene therapy, tissue engineering, and platelet rich plasma. On the basis of the application, the market is segmented into orthopedics, wound care, oncology, and others.

On the basis of distribution channel, the global regnerative medicine segments includes hospitals, clinics, and others. Cell therapy segmented is expected to register comparatively high CAGR during the forecast period due to increased research and product development in the field of stem cells.Regional Analysis

Asia Pacific is anticipated to register comparatively higher CAGR during the forecast period due to increased adoption of the platelet rich plasma therapy and growing awareness among the population about stem cell therapy and regenerative medicine

North America generated maximum revenue of USD 9,128.2 Mn in 2018 and is expected to dominate the market throughout the forecast period. Due to presence of substantial number of key market players based in U.S., presence of research institutes involved in development of novel therapeutics and availability of advanced technologies are attributive to the high number of clinical trials in North America. Asia Pacific is anticipated to witness exponential growth during the forecast period owing to expansion of infrastructure and facilities to accelerate stem cell research in developing countries. In April 2013, the Japan Ministry of Health, Labor and Welfare approved Regenerative Medicine law.

Asia Pacific Regenerative Medicine Market Size, 2018

The imposition of the law increased the number of the clinical development of regenerative and cell-based therapies. This led to drive the growth of the regenerative medicine market in the region. Additionally, Chinese government has approved several research related to human embryonic stem cells in order to encourage researchers to explore the clinical potential of these cells in China. Furthermore, rising aging population, increasing medical needs, and changing lifestyle are some of the other factors influencing the growth of the global regenerative market in the Asia Pacific region. Latin America, and Middle East & Africa region hold large potential for the market during 2019-2026.

Key Market Drivers

CELGENE CORPORATION, Medtronic, and American CryoStem Corporation Account for the Highest Market Share in Terms of Revenue

CELGENE CORPORATION, is a leading player in the global regenerative medicines, owing to its strong portfolio in wound care and orthopedics and more investment in the research and development of the regenerative medicine. In order to strengthen the market position, key market players are focusing on the introduction of organ development and treatment of chronic diseases in the global market. CELGENE CORPORATION, Medtronic, and American CryoStem Corporation, dominated the regenerative medicine market in 2018. Other players operating in the market are Avita Medical, Osiris Therapeutics, Inc., Tissue Regenix, Wright Medical Group N.V., Smith & Nephew, Integra LifeSciences Corporation and others.

List of Companies Profiled

Report Coverage

The potential to directly alter human genes was first recognized nearly more than 50 years ago. Cell and gene therapy, represent overlapping fields of biomedical research with similar therapeutic goals. Regenerative medicine also comprises of therapeutic tissue engineering and biomaterials engineered substances used in medical applications to supplement or replace a natural body function. The increased number of the clinical trials and the use of the regenerative medicine for the development of the medicine to treat chronic diseases are some of the factors propelling the regenerative medicine market trends.

The report provides qualitative and quantitative insights on the regenerative medicine industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The market is segments include type, application, distribution channel, and geography. On the basis of the type, the market is segmented into cell therapy, gene therapy, tissue engineering and platelet rich plasma. On the basis of the application, the market is segmented into orthopedics, wound care, oncology and others. On the basis of distribution channel, the regenerative medicine market is segmented into hospitals, clinics and others. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.

Along with this, the regenerative medicine market report comprises analysis of the industrydynamics and competitive landscape. Various key insights provided in the report are prevalence and incidence of diabetes by key countries, advancements in insulin delivery devices, recent industry developments such as mergers & acquisitions, pricing analysis, technological advancements, and key industry trends.

SEGMENTATION

By Product

By Application

By Distribution Channel

By Geography

Key Industry Developments

In 2018, Novartis received EU approval for one-time gene therapy Luxturna, which has been developed to restore vision in people with rare and genetically-associated retinal disease.

In 2018, Novartis received EU approval for its CAR-T cell therapy, Kymriah.In 2017, Integra LifeSciences launched its product, Integra Dermal Regeneration Template Single Layer Thin for dermal repair defects reconstruction in a one-step procedure.

Looking for more? Check out our repository for all available reports on Regenerative Medicine in related sectors.

Quick Read Table of Contents of this Report @ Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2020 2029 (Includes COVID-19 Business Impact)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read more:
Global regenerative medicine market size was USD 23841.5 Million in 2018 and is Projected to Reach USD 151949.5 Million by 2026, Exhibiting a CAGR of...

Two injections containing about five million stem cells delivered directly to Brodys hip jointsDuring last months surgery to address an issue with Brodys joints, Dr. Jeffrey Christiansen of Superior Veterinary Surgical Solutions collected a small amount of Brodys fat. (Brevard Zoo image)

BREVARD COUNTY MELBOURNE, FLORIDA During last months surgery to address an issue with Brodys joints, Dr. Jeffrey Christiansen of Superior Veterinary Surgical Solutions collected a small amount of Brodys fat.

A laboratory extracted stem cells from the fat sample, which can be used to reduce pain and inflammation and promote healing of the surgical site.

On Friday morning, Brody was brought back to the L3Harris Animal Care Center to receive his first dose of this medication.

Two injections containing about five million stem cells each were delivered directly to Brodys hip joints. To accomplish this, Dr. Christiansen carefully inserted a needle into Brodys hip and drew a small amount of joint fluid to confirm the tip was in the right place, then administered the injection.

A third, less-concentrated injection was delivered intravenously.

We also captured some radiographs to check on Brodys hip condition.

While we wont be able to evaluate the long-term effectiveness of the surgery for quite some time, he appears to be recovering without complication.

Brody woke from the anesthesia and was returned to his habitat. It is normal for animals to experience discomfort and lameness for a few days following stem-cell injections, but Brody is already back to being his normal, energetic self.

We have enough stem cells banked for an additional 15 doses, which will be administered throughout the course of Brodys life as needed.

Quality veterinary care is expensive. Click here to support animal wellness at the Zoo during this financially challenging time.

CLICK HERE FOR BREVARD COUNTY NEWS

Follow this link:
Brevard Zoo's Bear 'Brody' Received Radiographs and Underwent First Round of Stem-Cell Therapy - SpaceCoastDaily.com

Aug. 17 (UPI) -- Israel and United Arab Emirates stem cell therapy companies signed an agreement Monday to collaborate on researching potential treatment for COVID-19.

The accord between Israel's Pluristem Therapeutics and UAE's Abu Dhabi Stem Cells Center aims to capitalize on each company's expertise to develop therapies and regenerative medicines for the treatment of severe diseases including COVID-19, according to a joint statement.

Both companies have been treating COVID-19 patients with stem cells.

Pluristem has been treating COVID-19 patients with a placenta-based stem cell therapy. The U.S. Food and Drug Administration cleared the Israel stem cell therapy company in May for a Phase II study of the treatment for severe COVID-19 cases. Preliminary results released in May from compassionate-use programs in Israel and the United States were promising, showing that 75 percent of participants no longer needed mechanical ventilation within 28 days.

The Abu Dhabi Stem Cells Center has started a therapy that returns blood-based stem cells back into the patient's lungs as a fine mist through a nebulizer.

"We are extremely proud to partner with our colleagues at the ADSCC by sharing knowledge and expertise that we believe will advance healthcare within and across our borders," Pluristem CEO and President Yaky Yanay said in the statement.

The ADSCC's General Manager Dr. Yendry Ventura also commented on the deal in the statement.

"Pluristem is a major player in the cell therapy field with years of experience, a unique platform and robust clinical pipeline," Ventura said. "We are excited to join forces and to promote the research and development of cell therapies for the best of the patients and the human society as a whole."

The deal is the second cross-border agreement since President Donald Trump brokered a deal to normalize ties between Israel and the UAE. It follows a cross-border deal on Sunday between UAE-based APEX National Investment and Israel's TeraGroup to conduct research on the coronavirus.

See the article here:
Israel and UAE team up on stem cell therapy research for COVID-19 - UPI News

A recent report added by Market Study Report, LLC, on ' Stem Cell Therapy Market' provides a detailed analysis on the industry size, revenue forecasts and geographical landscape pertaining to this business space. Additionally, the report highlights primary obstacles and latest growth trends accepted by key players that form a part of the competitive spectrum of this business.

.

Request a sample Report of Stem Cell Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2422751?utm_source=Algosonline.com&utm_medium=AN

The latest document on Stem Cell Therapy market includes a wide-range analysis of this industry along with the thorough division of this vertical. According to the report, the Stem Cell Therapy market is likely to grow and increase a significant return over the estimated time period and will also record an outstanding growth rate y-o-y over the upcoming years.

According to the report, the research study provides valuable estimations about the Stem Cell Therapy market pertaining to the sales capacity, market size, profit projections, and numerous other crucial parameters. The Stem Cell Therapy market document also evaluates details about the industry segmentation as well as the driving forces that impact the remuneration scale of this industry.

Explaining the Stem Cell Therapy market with respect to the geographical landscape:

Ask for Discount on Stem Cell Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2422751?utm_source=Algosonline.com&utm_medium=AN

Listed below is a short outline of the major key takeaways of Stem Cell Therapy market report

The report evaluation of the Stem Cell Therapy market claims that the industry is expected to register a substantial revenue over the given time period. It includes data with respect to the market dynamics such as challenges present in this vertical, the possible growth opportunities, and the factors affecting the business domain.

For More Details On this Report: https://www.marketstudyreport.com/reports/global-stem-cell-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2025

Related Reports:

1. Global Quetiapine Fumarate Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Read More: https://www.marketstudyreport.com/reports/global-quetiapine-fumarate-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

2. Global Tracheotomy Tube Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Read More: https://www.marketstudyreport.com/reports/global-tracheotomy-tube-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Related Report : https://www.marketwatch.com/press-release/telecom-network-infrastructure-market-detailed-analysis-of-current-industry-figures-with-forecasts-growth-by-2026-2020-08-17?tesla=y

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Original post:
Global Stem Cell Therapy Market Growth, Size, Analysis, Outlook by 2020 - Trends, Opportunities and Forecast to 2025 - AlgosOnline

Damaged cartilage can be treated through a technique called microfracture, in which tiny holes are drilled in the surface of a joint. The microfracture technique prompts the body to create new tissue in the joint, but the new tissue is not much like cartilage.

Microfracture results in what is called fibrocartilage, which is really more like scar tissue than natural cartilage, said Chan. It covers the bone and is better than nothing, but it doesnt have the bounce and elasticity of natural cartilage, and it tends to degrade relatively quickly.

The most recent research arose, in part, through the work of surgeon Matthew Murphy, PhD, a visiting researcher at Stanford who is now at the University of Manchester. I never felt anyone really understood how microfracture really worked, Murphy said. I realized the only way to understand the process was to look at what stem cells are doing after microfracture. Murphy is the lead author on the paper. Chan and Longaker are co-senior authors.

For a long time, Chan said, people assumed that adult cartilage did not regenerate after injury because the tissue did not have many skeletal stem cells that could be activated. Working in a mouse model, the team documented that microfracture did activate skeletal stem cells. Left to their own devices, however, those activated skeletal stem cells regenerated fibrocartilage in the joint.

But what if the healing process after microfracture could be steered toward development of cartilage and away from fibrocartilage? The researchers knew that as bone develops, cells must first go through a cartilage stage before turning into bone. They had the idea that they might encourage the skeletal stem cells in the joint to start along a path toward becoming bone, but stop the process at the cartilage stage.

The researchers used a powerful molecule called bone morphogenetic protein 2 (BMP2) to initiate bone formation after microfracture, but then stopped the process midway with a molecule that blocked another signaling molecule important in bone formation, called vascular endothelial growth factor (VEGF).

What we ended up with was cartilage that is made of the same sort of cells as natural cartilage with comparable mechanical properties, unlike the fibrocartilage that we usually get, Chan said. It also restored mobility to osteoarthritic mice and significantly reduced their pain.

As a proof of principle that this might also work in humans, the researchers transferred human tissue into mice that were bred to not reject the tissue, and were able to show that human skeletal stem cells could be steered toward bone development but stopped at the cartilage stage.

The next stage of research is to conduct similar experiments in larger animals before starting human clinical trials. Murphy points out that because of the difficulty in working with very small mouse joints, there might be some improvements to the system they could make as they move into relatively larger joints.

The first human clinical trials might be for people who have arthritis in their fingers and toes. We might start with small joints, and if that works we would move up to larger joints like knees, Murphy says. Right now, one of the most common surgeries for arthritis in the fingers is to have the bone at the base of the thumb taken out. In such cases we might try this to save the joint, and if it doesnt work we just take out the bone as we would have anyway. Theres a big potential for improvement, and the downside is that we would be back to where we were before.

Longaker points out that one advantage of their discovery is that the main components of a potential therapy are approved as safe and effective by the FDA. BMP2 has already been approved for helping bone heal, and VEGF inhibitors are already used as anti-cancer therapies, Longaker said. This would help speed the approval of any therapy we develop.

Joint replacement surgery has revolutionized how doctors treat arthritis and is very common: By age 80, 1 in 10 people will have a hip replacement and 1 in 20 will have a knee replaced. But such joint replacement is extremely invasive, has a limited lifespan and is performed only after arthritis hits and patients endure lasting pain. The researchers say they can envision a time when people are able to avoid getting arthritis in the first place by rejuvenating their cartilage in their joints before it is badly degraded.

One idea is to follow a Jiffy Lube model of cartilage replenishment, Longaker said. You dont wait for damage to accumulate you go in periodically and use this technique to boost your articular cartilage before you have a problem.

Longaker is the Deane P. and Louise Mitchell Professor in the School of Medicine and co-director of the Institute for Stem Cell Biology and Regenerative Medicine. Chan is a member of the Institute for Stem Cell Biology and Regenerative Medicine and Stanford Immunology.

Other Stanford scientist taking part in the research were professor of pathology Irving Weissman, MD, the Virginia and D. K. Ludwig Professor in Clinical Investigation in Cancer Research; professor of surgery Stuart B. Goodman, MD, the Robert L. and Mary Ellenburg Professor in Surgery; associate professor of orthopaedic surgery Fan Yang, PhD; professor of surgery Derrick C. Wan, MD; instructor in orthopaedic surgery Xinming Tong, PhD; postdoctoral research fellow Thomas H. Ambrosi, PhD; visiting postdoctoral scholar Liming Zhao, MD; life science research professionals Lauren S. Koepke and Holly Steininger; MD/PhD student Gunsagar S. Gulati, PhD; graduate student Malachia Y. Hoover; former student Owen Marecic; former medical student Yuting Wang, MD; and scanning probe microscopy laboratory manager Marcin P. Walkiewicz, PhD.

The research was supported by the National Institutes of Health (grants R00AG049958, R01 DE027323, R56 DE025597, R01 DE026730, R01 DE021683, R21 DE024230, U01HL099776, U24DE026914, R21 DE019274, NIGMS K08GM109105, NIH R01GM123069 and NIH1R01AR071379), the California Institute for Regenerative Medicine, the Oak Foundation, the Pitch Johnson Fund, the Gunn/Olivier Research Fund, the Stinehart/Reed Foundation, The Siebel Foundation, the Howard Hughes Medical Institute, the German Research Foundation, the PSRF National Endowment, National Center for Research Resources, the Prostate Cancer Research Foundation, the American Federation of Aging Research and the Arthritis National Research Foundation.

Read this article:
Researchers find method to regrow cartilage in the joints - Stanford Medical Center Report